GeoVax to Present Key Updates on Vaccine and Cancer Therapy Programs at Investment Conference

GeoVax Labs, Inc. will present a company overview and host investor meetings during the H.C. Wainwright 27th Annual Global Investment Conference in New York City. Chairman and CEO David Dodd will discuss recent progress and upcoming milestones across the company's pipeline, including key programs in infectious disease vaccines and cancer therapies.

The presentation will cover GEO-MVA, a next-generation MVA-based Mpox/smallpox vaccine that recently received favorable Scientific Advice from the European Medicines Agency. This regulatory guidance positions the vaccine to support global preparedness and stockpile strategies, potentially accelerating its development path by omitting Phase 1 and Phase 2 trials and progressing directly to Phase 3 clinical evaluation.

GeoVax will also provide updates on GEO-CM04S1, the company's multi-antigen COVID-19 vaccine currently being evaluated in three Phase 2 clinical trials. These trials target various patient populations, including immunocompromised individuals such as those suffering from hematologic cancers and other patient groups for whom current authorized COVID-19 vaccines are insufficient. The vaccine is also being studied as a booster for patients with chronic lymphocytic leukemia and healthy patients who previously received mRNA vaccines.

The company will highlight Gedeptin®, its gene-directed enzyme prodrug therapy for solid tumors, including an upcoming Phase 2 trial in head and neck cancer. This novel oncolytic solid tumor therapy recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers, representing an important advancement in cancer treatment options.

GeoVax will emphasize how its MVA platform and U.S.-based continuous cell line manufacturing capabilities position the company to address critical gaps in vaccine supply diversification, pandemic readiness, and biosecurity. The company's strong intellectual property portfolio supports its technologies and product candidates, with worldwide rights for its innovations. A webcast of the presentation will be available through https://journey.ct.events/view/40d09ded-caa5-44ff-baf7-10795e9d5386 for those interested in the detailed updates.